Remove Blogging Remove Invest Remove San Diego Remove Thousand Oaks

Biotech Roundup: Scangos’s Exit, Zafgen’s Shakeup, Jounce, Relypsa & More

Xconomy

It’s the first partnership for Jounce, and a big one: the startup got a $225 million up front cash payment from Celgene and a $36 million equity investment. —Bruce Bigelow profiled Dauntless Pharmaceuticals , a stealthy biotech company creator in San Diego forming single-drug startups. —San Francisco gene therapy startup Audentes Pharmaceuticals (NASDAQ: BOLD ) raised $75 million in an IPO , selling 5 million shares at $15 apiece, right in its projected range.

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

—Pfizer won the auction for San Francisco cancer drug maker Medivation (NASDAQ: MDVN ) with a $14 billion all-cash bid—at $81.50 —San Carlos, CA-based BioCardia will also go public via a reverse merger , four months after dropping plans for an IPO.

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More

Xconomy

—Gene therapy news: After investing in Bamboo Therapeutics and its Duchenne muscular dystrophy treatment earlier this year, Pfizer bought the Chapel Hill, NC-based biotech outright on Monday for $150 million up front , with potentially another $495 million later. —Meanwhile, scientists from San Diego-based Synthetic Genomics and the J. Biogen was once again all over the biotech newswire this week.